Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines

• Main Authors: Seohyun Son (Author), Ahmed Elkamhawy (Author), Anam Rana Gul (Author), Ahmed A. Al‐Karmalawy (Author), Radwan Alnajjar (Author), Ahmed Abdeen (Author), Samah F. Ibrahim (Author), Saud O. Alshammari (Author), Qamar A. Alshammari (Author), Won Jun Choi (Author), Tae Jung Park (Author), Kyeong Lee (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) protein tyrosine kinases co-expressed in various cancers such as ovarian, breast, colon, and prostate subtypes. Herein, new TAK-285 derivatives (9a-h) were synthesised, characterised, and biologically evaluat...